What has been learned from measuring health-related quality of life in clinical oncology

European Journal of Cancer

Volumn 35, Issue 11, 1999, Pages 1565-1570

  Osoba, D ^a  

^a QOL Consulting   (Canada)

Author keywords

Clinical oncology; Health related quality of life

Indexed keywords

ALPHA2A INTERFERON; ANALGESIC AGENT; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; MEDROXYPROGESTERONE; MITOXANTRONE; PREDNISONE; TEMOZOLOMIDE;

ARTICLE; BREAST CANCER; CANCER; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; NAUSEA; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; VOMITING; WELLBEING;

CLINICAL TRIALS; HEALTH STATUS; HUMANS; MULTICENTER STUDIES; NEOPLASMS; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0032857448     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00192-6     Document Type: Article

References (69)

1. Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada. organization and functions Quality Life Res. 1:1992;211-218.
2. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in clinical trials. In Scheurlen H, Kay R, Baum M, eds. Cancer Clinical Trials; A Critical Appraisal. Recent Results in Cancer Research. Berlin, Springer, 1988, 111, 231-249.
3. Cella D.F., Bonomi A., Lloyd S.R.et al. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer. 12:1995;199-220.
4. Osoba D. Self-rating symptom checklists. a simple method for recording and evaluating symptom control in oncology Cancer Treat. Rev. 19(Suppl. A):1993;43-51.
5. Bjordal K., Kaasa S. Psychometric validation of the EORTC core quality of life questionnaire, a 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol. 31:1992;311-321.
6. Sadura A., Pater J., Osoba D.et al. Quality-of-life assessment. patient compliance with questionnaire completion J. Natl. Cancer Inst. 84:1992;1023-1026.
7. Hurny C., Bernhard J., Joss R.et al. Feasibility of quality of life assessment in a randomised phase III trial of small-cell lung cancer - a lesson from the real world. Ann. Oncol. 3:1992;825-831.
8. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J. Clin. Oncol. 12:1994;608-616.
9. Osoba D. Guidelines for measuring health-related quality of life in clinical trials. In Staquet MK, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials. Methods and Practice. Oxford, Oxford University Press, 1998, 19-35.
10. Osoba D., Dancey J., Zee B.et al. Health-related quality of life studies of the National Cancer Institute of Canada Clinical Trials Group. Monogr. Natl. Cancer Inst. 20:1996;107-111.
11. Osoba D., Zee B. Completion rates in health-related quality of life assessment. approach of the National Cancer Institute of Canada Clinical Trials Group Statist. Med. 17:1998;603-612.
12. Buxton J., White M., Osoba D. Patients' experiences using a computerized program with touch-sensitive monitor for the assessment of health-related quality of life. Quality Life Res. 7:1998;513-519.
13. Ganz P.A., Day R., Constantino J. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial. Statist. Med. 17:1998;613-622.
14. Kaasa S., Hjermslad M.J., Jordhoy M.S.et al. Compliance in quality of life data. a Norwegian experience Statist. Med. 17:1998;623-632.
15. Bernhard J., Gusset H., Hurny C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Research. Statist. Med. 17:1998;633-639.
16. Moinpour C.M., Lovato L.C. Ensuring the quality of life data. the Southwest Oncology Group experience Statist. Med. 17:1998;641-651.
17. Huisman SJ, van Dam FSAM, Aaronson NK, et al. On measuring complaints of cancer patients: some remarks on the time span of the question. In Aaronson, NK, Beckmann J, eds. The Quality of Life of Cancer Patients. New York, Raven Press, 1987, 101-109.
18. Pater J., Osoba D., Zee B.et al. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials. an example using the EORTC QLQ-C30 in a large anti-emetic trial Qual. Life Res. 7:1998;273-278.
19. Osoba D. Rationale for the timing of health-related quality of life assessments in oncological palliative therapy. Cancer Treat. Rev. 22(Suppl. A):1996;69-73.
20. Seymour M.T., Slevin M.L., Kerr D.J.et al. Randomised trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol. 14:1996;2282-2288.
21. Coates A., Gebski V., Bishop J.F.et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317:1987;1490-1495.
22. Grunfeld E., Mant D., Yudkin P.et al. Routine follow-up of breast cancer in primary care. randomised trial N. Engl. J. Med. 317:1987;1490-1495.
23. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br. J. Cancer. 73:1996;406-413.
24. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer. (SCLS) II. quality of life Br. J. Cancer. 68:1993;1157-1166.
25. Helsing M., Bergman B., Thaning L.et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur. J. Cancer. 34:1998;1036-1044.
26. Fernandez C., Rosell R., Abad-Esteve A. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol. 38(1):1989;29-33.
27. Porter A.T., McEwan A.J.B., Powe J.E.et al. Results of a randomised phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;805-813.
28. Allen-Mersch T.G., Earlam S., Fordy C.et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectoral liver metastases. Lancet. 244:1994;1255-1260.
29. Clavel M., Soukop M., Greenstreet Y.L.A. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology. 50:1993;180-185.
30. Rowland Jr K.M., Loprinzi C.L., Shaw E.G.et al. Randomised double-blind placebo controlled trial of cisplatin and etoposide plus megestrol acetate in extensive-stage small-cell lung cancer. A North Central Cancer Treatment Group Study J. Clin. Oncol. 14:1996;135-141.
31. Simons J.P.F.H.A., Aaronson N.K., Vansteenkiste J.F.et al. Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced-stage non-hormone-sensitive cancer. a placebo-controlled multicentre study J. Clin. Oncol. 14:1996;1077-1084.
32. Bruera E., Ernst S., Hagen N.et al. Effectiveness of megestrol acetate in patients with advanced cancer. a randomised, double-blind, crossover study Cancer Prev. Control. 2:1998;74-78.
33. Tannock I.F., Osoba D., Stockler M.R.et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. a Canadian randomised trial with palliative end points J. Clin. Oncol. 14:1996;1756-1764.
34. Osoba D., Tannock I.F., Ernst S., Neville J. Health-related quality of life in men with metastatic prostate cancer treated by prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol. 17:1999;1654-1663.
35. Osoba D, Levin V, Yung WKA, et al. Health-related quality of life (HRQL) benefits in patients with recurrent anaplastic astrocytoma (AA) treated with Temozalamide (TEM). Proc ASCO 1998, 17, 388a (abstract 1496).
36. Sutherland H.J., Lockwood G.A., Boyd N.F. Ratings of the importance of quality of life variables. therapeutic implications for patients with breast cancer J. Clin. Epidemiol. 43:1990;661-666.
37. Kornblith A.B., Herr H.W., Ofman U.S.et al. Quality of life of patients with prostate cancer and their spouses. The value of a database in clinical care. Cancer. 73:1994;2791-2802.
38. Hurny C., Bernhard J., Coates A.S.et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet. 347:1996;1279-1284.
39. Lindley C.M., Jursch J.D., O'Neil C.V.et al. Quality of Life consequences of chemotherapy-induced emesis. Qual. Life Res. 1:1992;331-340.
40. O'Brien B.J., Rusthoven J., Rocchi A.et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and costs. survey of five Canadian centres Can. Med. Assoc. J. 149:1993;296-302.
41. Osoba D., Zee B., Warr D.et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer. 5:1997;307-313.
42. Coates A., Gebski V., Signorini D.et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J. Clin. Oncol. 10:1992;1833-1838.
43. Coates A.S., Thomson D., McLeod G.R.M.et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur. J. Cancer. 29A:1993;1731-1734.
44. Dancey J., Zee B., Osoba D.et al. Quality of life score. an independent prognostic variable in a general population of cancer patients receiving chemotherapy Qual. Life Res. 6:1997;151-158.
45. Coates A., Porzsolt F., Osoba D. Quality of life in oncology practice. prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy Eur. J. Cancer. 33:1997;1025-1030.
46. Kaasa S., Mastekaasa A., Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. Radiother. Oncol. 15:1989;235-242.
47. Ruckdeschel J.C., Piantadosi S. The Lung Cancer Study Group. Quality of life assessment in lung surgery for bronchogenic carcinoma. J. Theoretical Surg. 6:1991;201-205.
48. Ganz P.A., Lee J.J., Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 67:1991;3131-3135.
49. Earlam S., Glover C., Fordy C.et al. Relation between tumour size, quality of life, and survival in patients with colorectoral liver metastates. J. Clin. Oncol. 14:1996;171-175.
50. Osoba D, Zee B, Sadura A, et al. Measurement of quality of life in an adjuvant trial of gamma interferon versus levamisole in malignant melanoma. In Salmon SE, ed. Adjuvant Therapy of Cancer VII. Philadelphia, Lippincott, 1993, 412-416.
51. Osoba D., Zee B., Pater J.et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J. Clin. Oncol. 15:1997;116-123.
52. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. ascertaining the minimal clinically important difference Controlled Clin. Trials. 10:1989;407-415.
53. Juniper E.D., Guyatt G.H., William A.et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 47:1994;81-87.
54. Osoba D., Rodrigues G., Myles J.et al. Interpreting the significance of health-related quality-of-life scores. J. Clin. Oncol. 16:1998;139-144.
55. King M.T. The Interpretation of scores from the EORTC quality of life questionnaire QLQ-30-C30. Qual. Life Res. 5:1996;555-556.
56. Ware J, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, The Health Institute, New England Medical Centre, 1994.
57. Sneeuw K.C.A., Aaronson N.K., Osoba D.et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med. Care. 5:1997;490-506.
58. Sneeuw K.C.A., Aaronson N.K., Sprangers M.A.F.et al. Value of caregiver ratings in evaluating the quality of life of patients with cancer. J. Clin. Oncol. 15:1997;1206-1217.
59. Fairclough D.L., Peterson H.F., Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Statist. Med. 17:1998;667-677.
60. Fairclough D.L., Peterson H.L., Cella D., Bonomi P. Comparisons of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statist. Med. 17:1998;781-796.
61. Zee B. Growth curve model analysis for quality of life data. Statist. Med. 17:1998;757-766.
62. Revicki D.A., Cella D.F. Health status assessment for the twenty-first century. item response theory, item banking and computer adaptive testing Qual. Life Res. 6:1997;595-600.
63. Kaplan RM, Anderson JP. The quality of well-being scale: rationale for a single quality of life index. In Walker SR, Rosser R, eds. Quality of Life: Assessment and Application. London, MTS Press, 1988, 51-77.
64. Feeny D, Torrance GW, Furlong W. Health utilities index. In Spilker V, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. New York, Raven-Lippincott Press, 1996.
65. Gelber R.D., Godlhirsch A. New endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J. Clin. Oncol. 4:1986;1772-1779.
66. Revicki D.A., Kaplan R.M. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality Life Res. 2:1993;477-487.
67. EuroQol. a new facility for the measurement of health-related quality of life Health Policy. 16:1990;199-208.
68. Curran D., Molenberghs G., Fayers P.M., Machin D. Incomplete quality of life data in randomised trials. missing forms Statist. Med. 17:1998;697-709.
69. Curran D., Bocchi M., Hsu Schmitz S.F.et al. Identifying the types of missingness in quality of life data from clinical trials. Statist. Med. 17:1998;739-756.